10-K: UnitedHealth Group Reports 41% Drop in Operating Earnings Amid Rising Medical Costs and Restructuring

UnitedHealth Group Incorporated announced a significant decline in 2025 operating earnings, driven by elevated medical costs and substantial restructuring charges, despite overall revenue growth.

Summary

• Consolidated revenues grew 12% to $447,567 million in 2025, with UnitedHealthcare revenues up 16% and Optum revenues up 7%.
• Earnings from operations decreased 41% to $18,964 million in 2025, compared to $32,287 million in 2024.
• Net earnings attributable to UnitedHealth Group common shareholders fell 16% to $12,056 million.
• Diluted earnings per common share decreased 15% to $13.23.
• The Medical Care Ratio (MCR) increased to 89.1% in 2025 from 85.5% in 2024, reflecting higher medical costs relative to premiums.
• Operating margin declined to 4.2% in 2025 from 8.1% in 2024.
• Optum Health reported a loss from operations of $(278) million, a 104% decrease from the prior year.
• Restructuring and other actions in Q4 2025 resulted in a $2.5 billion impact, including $746 million for real estate rationalization and workforce reductions, and a $623 million loss contract reserve for anticipated future losses in value-based care businesses.
• Increased reserves of $799 million were recorded for net collection expectations related to provider loans following the 2024 Change Healthcare cyberattack.
• The company's Board of Directors increased the quarterly cash dividend to an annual rate of $8.84 per share, up from $8.40 per share in June 2024.
• UnitedHealthcare served 415,000 more people domestically, driven by growth in fee-based commercial offerings and Medicare Advantage, partially offset by declines in risk-based commercial and Medicaid offerings.
• Optum Health served 95 million people, a decrease from 100 million in 2024.
• Optum Rx fulfilled 1,659 million adjusted scripts in 2025, up from 1,623 million in 2024, contributing to a 16% revenue increase and 23% earnings increase for the segment.
• The effective income tax rate decreased to 12.9% due to tax benefits having a greater impact on lower pre-tax income and net portfolio divestitures.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for UnitedHealth Group, marked by significant declines in profitability and increased medical costs, despite revenue growth. The restructuring and cyberattack impacts further weigh on performance, indicating operational headwinds.

Positives

• Consolidated revenues increased by 12% to $447,567 million in 2025.
• UnitedHealthcare revenues grew 16% and Optum Rx revenues grew 16%.
• UnitedHealthcare increased its domestic customer base by 415,000 people, with notable growth in Medicare Advantage (600,000 people) and fee-based commercial offerings (600,000 people).
• Optum Rx saw increased script volumes and growth in pharmacy services, leading to a 23% increase in earnings from operations.
• The Board of Directors increased the quarterly cash dividend to an annual rate of $8.84 per share.
• Net portfolio divestitures in Q4 2025 resulted in a net gain of $568 million, including a $1.5 billion gain at Optum Rx.

Negatives

• Earnings from operations decreased significantly by 41% to $18,964 million in 2025.
• Net earnings attributable to common shareholders decreased 16% to $12,056 million.
• Diluted earnings per common share decreased 15% to $13.23.
• The Medical Care Ratio (MCR) increased to 89.1%, indicating higher medical costs relative to premiums.
• Operating margin decreased to 4.2% from 8.1% in the prior year.
• Optum Health experienced a loss from operations of $(278) million, a 104% decrease, impacted by Medicare Advantage funding reductions and elevated medical cost trends.
• Restructuring and other actions in Q4 2025 had a $2.5 billion impact, including $746 million for workforce reductions and real estate rationalization.
• A $623 million loss contract reserve was established for anticipated future losses in certain value-based care businesses within Optum Health.
• Increased reserves of $799 million were recorded for uncollectible provider loans related to the Change Healthcare cyberattack.
• Medicare Advantage funding continues to be pressured, and the company expects Medicare Advantage membership to contract in 2026.
• Medicaid membership losses are expected in 2026 due to reduced eligibility and exit from one state.

Risks

• Failure to accurately estimate, price for, and manage medical costs could materially and adversely affect profitability.
• Risks related to the integrity and availability of data, including potential failures in information systems and technology products (especially those incorporating AI).
• Exposure to cyberattacks and other privacy or data security incidents, which could lead to operational disruptions, financial liability, and reputational harm.
• Challenges in developing and maintaining satisfactory relationships with healthcare payers, physicians, hospitals, and other service providers.
• Intense competition in all markets, potentially leading to loss of market share if the company fails to innovate or compete effectively.
• Routine exposure to private party and governmental legal actions and investigations, which could result in substantial penalties or monetary damages.
• Legal, regulatory, and business risks associated with the increasing use of AI technologies.
• Difficulties in successfully managing strategic alliances, or completing and integrating acquisitions and other significant strategic transactions.
• Risks from public health crises, natural disasters, and other extreme events impacting business operations and increasing medical costs.
• Failure to attract, develop, retain, and manage the succession of key employees and executives.
• Potential losses in the investment and loan portfolio due to market fluctuations.
• Risk of material impairment to goodwill and other intangible assets, which could adversely affect results of operations, equity, and credit ratings.
• Highly regulated business environment with frequent and unpredictable changes in laws and regulations, potentially increasing compliance costs or restricting business models.
• Exposure to additional risks from government health care programs, including funding reductions, payment adjustments, audits, and investigations.
• Regulatory and operational risks specific to pharmacy care services businesses, including new legislation and investigations into PBM practices.
• Restrictions on the ability to obtain funds from regulated subsidiaries, impacting reinvestment, debt servicing, and capital returns to shareholders.

Future Outlook

The company anticipates continued growth in overall healthcare spending due to inflation, medical technology advancements, and demographic trends. However, it expects Medicare Advantage membership to contract in 2026 due to ongoing funding pressures and increased pricing. The number of people served under value-based care arrangements is also expected to contract. Medicaid margins face continued downward pressure due to elevated care activity and insufficient state rate updates. The company plans to accelerate the transition to fully accountable value-based care models, which will require initial costs for system enhancements and integrated care coordination. The sale of remaining South American operations is expected to close in the second half of 2026.

Management Comments

• Our two distinct, yet complementary businesses – Optum and UnitedHealthcare – are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.
• We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being.
• For 2025, our pricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred, significantly impacting our earnings.
• We have observed increased care patterns that are above what we expected and contemplated in our pricing and benefits design.
• We endeavor to mitigate medical cost increases by engaging hospitals, physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care.
• We continue to advocate for actuarially sound rates commensurate with our medical cost trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs.

Industry Context

StockSavvy.ai notes that UnitedHealth Group's performance reflects broader industry challenges, including persistent medical cost inflation and evolving regulatory landscapes, particularly in government-sponsored programs like Medicare Advantage and Medicaid. The company's strategic focus on value-based care and digital health technologies aligns with industry trends towards integrated, patient-centered care and administrative efficiency. However, the significant decline in operating earnings and increased MCR highlight the difficulties even industry leaders face in managing costs and pricing in a dynamic healthcare environment. The cyberattack on Change Healthcare underscores the increasing vulnerability of the healthcare sector to sophisticated digital threats.

Comparison to Industry Standards

• The increase in the Medical Care Ratio (MCR) to 89.1% suggests that UnitedHealth Group's medical cost management in 2025 was less effective compared to its own historical performance (85.5% in 2024, 83.2% in 2023) and potentially compared to some industry peers, although specific peer data is not provided in this filing.
• The 41% decrease in earnings from operations is a substantial underperformance relative to typical expectations for a large, diversified healthcare company, indicating significant headwinds not fully offset by revenue growth.
• The company's continued investment in value-based care models and digital health technologies is consistent with leading healthcare organizations aiming to improve outcomes and reduce costs, such as Kaiser Permanente or Humana, which also emphasize integrated care delivery.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a lawsuit initiated by a whistleblower in 2011, with the DOJ pursuing claims since 2017, alleging improper risk adjustment submissions and False Claims Act violations. A Special Master recommended summary judgment in the company's favor in March 2025, but the DOJ filed a motion to reject this in April 2025, making the outcome uncertain.
• The company is routinely subject to various governmental investigations, audits, and reviews by agencies such as CMS, OIG, DOJ, SEC, and state regulators, covering compliance with coding, risk-adjustment models, and other requirements.
• Risk adjustment data validation (RADV) audits by CMS and OIG have resulted and may continue to result in retrospective adjustments to payments, fines, or other adverse actions for the company's health plans.
• The company is exposed to legal actions related to health care benefits coverage, claims payment disputes, tort claims (including medical malpractice), antitrust claims, whistleblower claims, data security incidents, and contract/labor disputes.

Related Party Transactions

• Transactions between UnitedHealthcare and Optum segments (e.g., Optum Rx selling pharmacy services to UnitedHealthcare, Optum Health providing care delivery to UnitedHealthcare) are recorded at management's estimate of fair value and eliminated in consolidation.

Stakeholder Impact

• **Shareholders**: Experienced a significant decrease in earnings and diluted EPS, potentially impacting investor confidence. However, the increased dividend and ongoing share repurchase program may provide some support. The long-term strategic focus on value-based care could offer future growth.
• **Employees**: Workforce reductions were part of the Q4 2025 restructuring actions, impacting some employees. Executive compensation plans (stock options, RSUs, PRSUs) are in place, and the company emphasizes attracting and retaining qualified talent.
• **Customers/Patients**: Face potential impacts from increased medical costs, which may influence future pricing and benefit design. The company aims to improve access, affordability, outcomes, and experiences through its integrated care models.
• **Care Providers**: Were impacted by the Change Healthcare cyberattack, with the company providing interest-free loans. The company's relationships with providers are crucial, and the transition to value-based care models will affect how providers interact with the company.
• **Regulators**: The company is under extensive scrutiny from various federal and state agencies, with ongoing investigations and audits, which could lead to fines or changes in business practices. Compliance with evolving regulations, especially concerning AI and data privacy, is a continuous challenge.

Next Steps

• Recast prior period segment financial information to conform to the 2026 presentation, starting with the Quarterly Report on Form 10-Q for Q1 2026.
• Close the sale of remaining South American operations in the second half of 2026.
• Continue to evaluate and adjust pricing and benefit design in local markets, especially for individual exchange products and Medicare Advantage, in response to increased medical costs and funding pressures.
• Intensify medical and operating cost management and make changes to care provider networks to address Medicare Advantage funding pressures.
• Continue to advocate for actuarially sound Medicaid rates commensurate with medical cost trends.
• Accelerate the transition from fee-for-service to fully accountable value-based care models, including investments in system enhancements and integrated care coordination technology.
• Monitor and respond to ongoing governmental investigations, audits, and reviews, including the DOJ lawsuit regarding risk adjustment submissions.

Key Dates

Recommendation

UnitedHealth Group's 2025 results show a substantial decline in operating earnings and EPS, primarily due to higher medical costs and significant restructuring charges. While revenue growth remains strong across most segments, the profitability pressures, particularly in Optum Health and Medicare Advantage, are concerning. The ongoing legal and regulatory scrutiny, coupled with the impacts of the Change Healthcare cyberattack, add to the uncertainty. However, the company's diversified business model, strategic investments in value-based care, and continued dividend increases provide a degree of stability. A 'hold' recommendation is appropriate as investors should monitor the effectiveness of cost management initiatives and the impact of regulatory changes on future profitability before making further investment decisions.

Keywords

UnitedHealth Group, UNH, Healthcare, Health Insurance, Managed Care, Optum, UnitedHealthcare, Medicare Advantage, Medicaid, Pharmacy Benefit Management, PBM, Medical Costs, Earnings, Revenue, Cybersecurity, Risk Factors, SEC Filing, 10-K, Financial Results, Restructuring, Dividends, Share Repurchase, Value-Based Care, AI in Healthcare